Formed AHC and CCI in 1980. Developed numerous drugs including Skin Cancer Drugs and the Biotechnology line of products. Formed a strategic partnership with David Suliman and was appointed chairman of the board in 2000 Since I developed the Moisture Magnet Tech to treat and cure skin disease include Cancer . On today market I have developed MMT Extra Strength skin Drugs. over 50 products to be distributed in USA and Worldwide with success. In addition I create the Sunscreen spectrum system the FDA has to adopt it in its system. There is a lot of work to be done and still I will give more on the years to come.

Dr David he is Vice President of CCI & AHC and Vice Charmin, He built business across strong economies including the USA, Canada and Europe. Expanded to cover emerging markets in the Middle East, South America, and Africa. During his tenure, he has managed to transform AHC from a small neighborhood company into a conglomerate with world wide factories producing some of the most technically advanced internationally branded products in the world. His Know how and Knowledge in the International Business put AHC & CCI from the top company integrity and good reputation to work with.

Mr. HISHAM JEBRIL, He obtained his degree in Electrical Engineering in 1984 preceded by a Master’s degree in Power Electronics in 1985, where he graduated as the summa cum laude with honours. He now has more than 35 years of experience in the industrial and machinery market, and he is widely esteemed as one of the most knowledgeable and experienced at the Pharmaceutical Industrial Processing Equipment engineering. He is responsible for to design all AHC equipment for all our Pharma worldwide. He joined AHC Board in 2010.

The pharma industry in the USA and globally is on a constant growth curve. In the dynamic milieu of this flourishing sector, the FDA government regulation office and policy changes always on a roll. AHC is a trend setter when it comes to obtaining FDA permissions & approvals. AHC has a distinguished regulatory department specifically for FDA regularity approvals. The department in coordination with New Product Development Team works towards the needs and wants of the business partners. The Bio-Equivalence studies & Clinical trials are also arranged by the said department as and when asked by FDA and various country’s organization as EPA and Health & Human Services of health for registration of the products. Joined the AHC board in 2010.

Started work in R&D developing OTC and Prescription Drugs. In 2005 assumed responsibility for all plant operations. Joined the AHC board in 2015.

Developed financial plans and computer technology that led his company from a small producer to the top of the industry in 10 years. Joined the AHC board in 2010.

Invented many laboratory and manufacturing techniques. Has expertise on complicated systems and instrumentation vital to pharmaceutical manufacturing. Joined the AHC board in 2017.

Major prescription drugs take years to develop. Michael helped decide the drugs to produce then produced the detailed plans for getting it approved and into production. He joined AHC board in 2010.

Citizen of England. Was assigned to the Middle East for years. Works with Dr Suliman developing Middle East and European strategy. Joined the AHC board in 2016.

In charge of all social media, web design and computer systems. Currently, finalizing an advanced computer manufacturing system. Joined the AHC board in 2018.